MET and non-small cell lung carcinoma: This is consistent with the high rate of concomitant TP53 mutations in MET amplified NSCLCs [11,12] and with our previous findings showing that up to 60% of EGFRm+ NSCLC patients with MET amplification and/or MET overexpression also harbored a TP53 mutation [32].